Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

 
• By Joseph Haas

While Intercept is calling it quits in NASH with its FXR agonist obeticholic acid following a second complete response letter, other companies are staying the course with Phase II molecules in the class.

Dominoes
Intercept followed a second CRL by announcing its exit from NASH R&D • Source: Shutterstock

More from New Products

More from Scrip